Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans

Biological Psychiatry

Volumn 72, Issue 10, 2012, Pages 871-879

  Ranganathan, Mohini ^a,b,c   Schnakenberg, Ashley ^a,b,c   Skosnik, Patrick D ^a,b,c   Cohen, Bruce M ^d,e   Pittman, Brian ^b,c   Sewell, R Andrew ^a,b,c   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MCLEAN HOSPITAL   (United States)

Author keywords

opioid; Hallucinogen; perception; psychosis; Salvia; Salvinorin A

Indexed keywords

HYDROCORTISONE; PLACEBO; PROLACTIN; SALVINORIN A;

ADULT; ANESTHESIA MECHANISM; ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; NORMAL HUMAN; PERCEPTION; PHARMACODYNAMICS; POWER SPECTRUM; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADULT; CARDIOVASCULAR SYSTEM; COGNITION; CROSS-OVER STUDIES; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ELECTROENCEPHALOGRAPHY; EUPHORIA; FEMALE; HALLUCINOGENS; HUMANS; HYDROCORTISONE; MALE; PERCEPTION; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, OPIOID, KAPPA; SENSATION; STREET DRUGS;

EID: 84867746318     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.06.012     Document Type: Article

References (88)

1. C. Chavkin, S. Sud, W. Jin, J. Stewart, J.K. Zjawiony, D.J. Siebert Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations J Pharmacol Exp Ther 308 2004 1197 1203
2. D. Gonzalez, J. Riba, J.C. Bouso, G. Gomez-Jarabo, M.J. Barbanoj Pattern of use and subjective effects of Salvia divinorum among recreational users Drug Alcohol Depend 85 2006 157 162
3. B.L. Roth, K. Baner, R. Westkaemper, D. Siebert, K.C. Rice, S. Steinberg Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist Proc Natl Acad Sci U S A 99 2002 11934 11939
4. J.A. Ford, W.C. Watkins, L. Blumenstein Correlates of Salvia divinorum use in a national sample: findings from the 2009 National Survey on Drug Use and Health Addict Behav 36 2011 1032 1037
5. M.J. Baggott, E. Erowid, F. Erowid, G.P. Galloway, J. Mendelson Use patterns and self-reported effects of Salvia divinorum: An internet-based survey Drug Alcohol Depend 111 2010 250 256
6. J.E. Lange, J. Daniel, K. Homer, M.B. Reed, J.D. Clapp Salvia divinorum: Effects and use among YouTube users Drug Alcohol Depend 108 2010 138 140
7. P.P. Nyi, E.P. Lai, D.Y. Lee, S.A. Biglete, G.I. Torrecer, I.B. Anderson Influence of age on Salvia divinorum use: Results of an Internet survey J Psychoactive Drugs 42 2010 385 392
8. H.R. Sumnall, F. Measham, S.D. Brandt, J.C. Cole Salvia divinorum use and phenomenology: Results from an online survey J Psychopharmacol 25 2010 1496 1507
9. M. Paulzen, G. Grunder Toxic psychosis after intake of the hallucinogen salvinorin A J Clin Psychiatry 69 2008 1501 1502
10. D. Gonzalez, J. Riba, J.C. Bouso, G. Gomez-Jarabo, M.J. Barbanoj Pattern of use and subjective effects of Salvia divinorum among recreational users Drug Alcohol Depend 85 2006 157 162
11. T.A. Vortherms, B.L. Roth Salvinorin A: from natural product to human therapeutics Mol Interv 6 2006 257 265
12. S. Pichini, S. Abanades, M. Farre, M. Pellegrini, E. Marchei, R. Pacifici Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking Rapid Commun Mass Spectrom 19 2005 1649 1656
13. M.W. Johnson, K.A. MacLean, C.J. Reissig, T.E. Prisinzano, R.R. Griffiths Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum Drug Alcohol Depend 115 2011 150 155
14. J.E. Mendelson, J.R. Coyle, J.C. Lopez, M.J. Baggott, K. Flower, E.T. Everhart Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: A placebo-controlled trial Psychopharmacology (Berl) 214 2011 933 939
15. D.J. Siebert Salvia divinorum and salvinorin A: New pharmacologic findings J Ethnopharmacol 43 1994 53 56
16. P.H. Addy Acute and post-acute behavioral and psychological effects of salvinorin A in humans Psychopharmacology (Berl) 220 2012 195 204
17. J.E. Pascoe, K.L. Williams, P. Mukhopadhyay, K.C. Rice, J.H. Woods, M.C. Ko Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys Psychoneuroendocrinology 33 2008 478 486
18. S.P. Blackford, P.J. Little, C.M. Kuhn Mu- and kappa-opiate receptor control of prolactin secretion in rats: Ontogeny and interaction with serotonin Endocrinology 131 1992 2891 2897
19. E. Ur, D.M. Wright, P.M. Bouloux, A. Grossman The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man Br J Pharmacol 120 1997 781 784
20. C. Coltro Campi, G.D. Clarke Effects of highly selective kappa-opioid agonists on EEG power spectra and behavioural correlates in conscious rats Pharmacol Biochem Behav 51 1995 611 616
21. G. Valenza, M.C. Carboncini, A. Virgillito, I. Creatini, L. Bonfiglio, B. Rossi EEG complexity drug-induced changes in disorders of consciousness: A preliminary report Conf Proc IEEE Eng Med Biol Soc 2011 2011 3724 3727
22. M.K. Greenwald, T.A. Roehrs Mu-opioid self-administration vs passive administration in heroin abusers produces differential EEG activation Neuropsychopharmacology 30 2005 212 221
23. K.B. Bocker, C.C. Hunault, J. Gerritsen, M. Kruidenier, T.T. Mensinga, J.L. Kenemans Cannabinoid modulations of resting state EEG theta power and working memory are correlated in humans J Cogn Neurosci 22 2010 1906 1916
24. N.C. Venables, E.M. Bernat, S.R. Sponheim Genetic and disorder-specific aspects of resting state EEG abnormalities in schizophrenia Schizophr Bull 35 2009 826 839
25. S.R. Sponheim, B.A. Clementz, W.G. Iacono, M. Beiser Clinical and biological concomitants of resting state EEG power abnormalities in schizophrenia Biol Psychiatry 48 2000 1088 1097
26. J.M. Hooker, T.A. Munro, C. Beguin, D. Alexoff, C. Shea, Y. Xu Salvinorin A and derivatives: Protection from metabolism does not prolong short-term, whole-brain residence Neuropharmacology 57 2009 386 391
27. B.E. Perron, B.K. Ahmedani, M.G. Vaughn, J.E. Glass, A. Abdon, L.T. Wu Use of Salvia divinorum in a Nationally Representative Sample Am J Drug Alcohol Abuse 38 2011 108 113
28. D.C. D'Souza, E. Perry, L. MacDougall, Y. Ammerman, T. Cooper, Y.T. Wu The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis Neuropsychopharmacology 29 2004 1558 1572
29. S.R. Kay, A. Fiszbein, L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
30. O.J. Mason, C.J. Morgan, A. Stefanovic, H.V. Curran The psychotomimetic states inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis Schizophr Res 103 2008 138 142
31. J.D. Bremner, J.H. Krystal, F.W. Putnam, S.M. Southwick, C. Marmar, D.S. Charney Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS) J Trauma Stress 11 1998 125 136
32. R.J. Strassman, C.R. Qualls, E.H. Uhlenhuth, R. Kellner Dose-response study of N,N-dimethyltryptamine in humans II. Subjective effects and preliminary results of a new rating scale Arch Gen Psychiatry 51 1994 98 108
33. R.J. Strassman Human psychopharmacology of N,N-dimethyltryptamine Behav Brain Res 73 1996 121 124
34. D. Wechsler Administration and Scoring Manual for the Wechsler Adult Intelligence Scale 3rd ed. 1997 The Psychological Corporation San Antonio, TX
35. E. Brunner, S. Domhof, F. Langer Nonparametric Analysis of Longitudinal Data in Factorial Experiments 2002 John Wiley and Sons New York
36. J.H. Krystal, E. Perry, R. Gueorguieva, A. Belger, S. Madonick, A. A-D Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function Arch Gen Psychiatry 62 2005 985 994
37. E.R. Butelman, M. Mandau, K. Tidgewell, T.E. Prisinzano, V. Yuferov, M.J. Kreek Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans J Pharmacol Exp Ther 320 2007 300 306
38. E.R. Butelman, T.J. Harris, M. Kreek Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys Eur J Pharmacol 383 1999 305 309
39. E.R. Butelman, M.J. Kreek kappa-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists Eur J Pharmacol 423 2001 243 249
40. D. Peckys, G.B. Landwehrmeyer Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study Neuroscience 88 1999 1093 1135
41. L.J. Sim-Selley, J.B. Daunais, L.J. Porrino, S.R. Childers Mu and kappa1 opioid-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in cynomolgus monkey brain Neuroscience 94 1999 651 662
42. W.A. Carlezon Jr, C. Beguin, J.A. DiNieri, M.H. Baumann, M.R. Richards, M.S. Todtenkopf Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats J Pharmacol Exp Ther 316 2006 440 447
43. Y. Zhang, E.R. Butelman, S.D. Schlussman, A. Ho, M.J. Kreek Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors Psychopharmacology (Berl) 179 2005 551 558
44. M. Grilli, E. Neri, S. Zappettini, F. Massa, A. Bisio, G. Romussi Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals Neuropharmacology 57 2009 523 530
45. B. Bromm, R. Ganzel, W.M. Herrmann, W. Meier, E. Scharein Pentazocine and flupirtine effects on spontaneous and evoked EEG activity Neuropsychobiology 16 1986 152 156
46. A. Wikler Clinical and electroencephalographic studies on the effects of mescaline, N-allylnormorphine and morphine in man; a pharmacologic analysis of the functions of the spontaneous electrical activity of the cerebral cortex J Nerv Ment Dis 120 1954 157 175
47. J. Riba, P. Anderer, A. Morte, G. Urbano, F. Jane, B. Saletu Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers Br J Clin Pharmacol 53 2002 613 628
48. A. Maksimow, M. Sarkela, J.W. Langsjo, E. Salmi, K.K. Kaisti, A. Yli-Hankala Increase in high frequency EEG activity explains the poor performance of EEG spectral entropy monitor during S-ketamine anesthesia Clin Neurophysiol 117 2006 1660 1668
49. B.A. Donzanti, J.S. Althaus, M.M. Payson, P.F. Von Voigtlander Kappa agonist-induced reduction in dopamine release: site of action and tolerance Res Commun Chem Pathol Pharmacol 78 1992 193 210
50. R. Spanagel, A. Herz, T.S. Shippenberg Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway Proc Natl Acad Sci U S A 89 1992 2046 2050
51. G. Di Chiara, A. Imperato Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats J Pharmacol Exp Ther 244 1988 1067 1080
52. Y. Zhang, E.R. Butelman, S.D. Schlussman, A. Ho, M.J. Kreek Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice Psychopharmacology (Berl) 173 2004 146 152
53. T.S. Shippenberg, A. Herz Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists Brain Res 436 1987 169 172
54. R. Bals-Kubik, A. Herz, T.S. Shippenberg Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated Psychopharmacology (Berl) 98 1989 203 206
55. T. Suzuki, Y. Shiozaki, Y. Masukawa, M. Misawa, H. Nagase The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference Jpn J Pharmacol 58 1992 435 442
56. T. Mori, M. Nomura, H. Nagase, M. Narita, T. Suzuki Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats Psychopharmacology (Berl) 161 2002 17 22
57. C.A. Crawford, S.A. McDougall, C.A. Bolanos, S. Hall, S.P. Berger The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity Psychopharmacology (Berl) 120 1995 392 399
58. S.D. Glick, I.M. Maisonneuve, J. Raucci, S. Archer Kappa opioid inhibition of morphine and cocaine self-administration in rats Brain Res 681 1995 147 152
59. S.D. Glick, K.E. Visker, I.M. Maisonneuve Effects of cyclazocine on cocaine self-administration in rats Eur J Pharmacol 357 1998 9 14
60. A.V. Kuzmin, S. Semenova, M.A. Gerrits, E.E. Zvartau, J.M. Van Ree Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice Eur J Pharmacol 321 1997 265 271
61. S. Schenk, B. Partridge, T.S. Shippenberg U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking Psychopharmacology (Berl) 144 1999 339 346
62. C.A. Heidbreder, S.R. Goldberg, T.S. Shippenberg The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat Brain Res 616 1993 335 338
63. L.J. Vanderschuren, A.N. Schoffelmeer, G. Wardeh, T.J. De Vries Dissociable effects of the kappa-opioid receptor agonists bremazocine, U69593, and U50488H on locomotor activity and long-term behavioral sensitization induced by amphetamine and cocaine Psychopharmacology (Berl) 150 2000 35 44
64. S.L. Collins, R.M. Gerdes, C. D'Addario, S. Izenwasser Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity Behav Pharmacol 12 2001 237 245
65. S. Schenk, B. Partridge, T.S. Shippenberg Reinstatement of extinguished drug-taking behavior in rats: Effect of the kappa-opioid receptor agonist, U69593 Psychopharmacology (Berl) 151 2000 85 90
66. W. Sun, Y. Xue, Z. Huang, J.D. Steketee Regulation of cocaine-reinstated drug-seeking behavior by kappa-opioid receptors in the ventral tegmental area of rats Psychopharmacology (Berl) 210 2010 179 188
67. A.S. Morani, B. Kivell, T.E. Prisinzano, S. Schenk Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats Pharmacol Biochem Behav 94 2009 244 249
68. T.S. Shippenberg, A. LeFevour, C. Heidbreder kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine J Pharmacol Exp Ther 276 1996 545 554
69. A.S. Morani, S. Schenk, T.E. Prisinzano, B.M. Kivell A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats Behav Pharmacol 23 2012 162 170
70. A.S. Morani, B. Kivell, T.E. Prisinzano, S. Schenk Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats Pharmacol Biochem Behav 94 2009 244 249
71. Y. Zhang, E.R. Butelman, S.D. Schlussman, A. Ho, M.J. Kreek Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors Psychopharmacology (Berl) 179 2005 551 558
72. D. Braida, V. Limonta, V. Capurro, P. Fadda, T. Rubino, P. Mascia Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward Biol Psychiatry 63 2008 286 292
73. M.S. Todtenkopf, J.F. Marcus, P.S. Portoghese, W.A. Carlezon Jr Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats Psychopharmacology (Berl) 172 2004 463 470
74. J.L. Neumeyer, N.K. Mello, S.S. Negus, J.M. Bidlack Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse Pharm Acta Helv 74 2000 337 344
75. T.E. Prisinzano, K. Tidgewell, W.W. Harding Kappa opioids as potential treatments for stimulant dependence AAPS J 7 2005 E592 E599
76. H.C. Tomasiewicz, M.S. Todtenkopf, E.H. Chartoff, B.M. Cohen, W.A. Carlezon Jr The kappa-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward Biol Psychiatry 64 2008 982 988
77. N.K. Mello, S.S. Negus Interactions between kappa opioid agonists and cocaine Preclinical studies Ann N Y Acad Sci 909 2000 104 132
78. R.B. Rothman, D.A. Gorelick, S.J. Heishman, P.R. Eichmiller, B.H. Hill, J. Norbeck An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence J Subst Abuse Treat 18 2000 277 281
79. S.D. Mague, A.M. Pliakas, M.S. Todtenkopf, H.C. Tomasiewicz, Y. Zhang, W.C. Stevens Jr Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats J Pharmacol Exp Ther 305 2003 323 330
80. R.F. Mucha, A. Herz Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning Psychopharmacology (Berl) 86 1985 274 280
81. T.S. Shippenberg, A. Herz Differential effects of mu and kappa opioid systems on motivational processes NIDA Res Monogr 75 1986 563 566
82. S.L. Walsh, E.C. Strain, M.E. Abreu, G.E. Bigelow Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans Psychopharmacology (Berl) 157 2001 151 162
83. S.L. Walsh, B. Geter-Douglas, E.C. Strain, G.E. Bigelow Enadoline and butorphanol: Evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans J Pharmacol Exp Ther 299 2001 147 158
84. M.L. Wadenberg A review of the properties of spiradoline: A potent and selective kappa-opioid receptor agonist CNS Drug Rev 9 2003 187 198
85. R. Vohra, A. Seefeld, F.L. Cantrell, R.F. Clark Salvia divinorum: Exposures reported to a statewide poison control system over 10 years J Emerg Med 40 2011 643 650
86. P. Przekop, T. Lee Persistent psychosis associated with salvia divinorum use Am J Psychiatry 166 2009 832
87. A. Abi-Dargham Do we still believe in the dopamine hypothesis? New data bring new evidence Int J Neuropsychopharmacol 7 suppl 1 2004 S1 S5
88. M. Bortolato, G.N. Aru, R. Frau, M. Orru, M. Fa, M. Manunta Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats Biol Psychiatry 57 2005 1550 1558